Related Experiment Videos
Mechanism of action and clinical trials of Mpl ligand
1Amgen, Inc., Thousand Oaks, CA 91320, USA.
Abstract:
Mpl ligand is the hematopoietic growth factor responsible for regulating the production of platelets. Since its discovery just 3 years ago, it has provided both unique insights into megakaryocytopoiesis and the means to stimulate platelet production in numerous clinical situations. In animals deficient in Mpl ligand, the number of megakaryocytes and platelets decreases by more than 80%. In addition to having an effect on the megakaryocyte lineage, Mpl ligand supports the growth of stem cells, multipotential cells, and erythroid precursors. The endogenous Mpl ligand, thrombopoietin, is produced in the liver and kidneys, and circulating levels appear to be regulated primarily by the mass of platelets and megakaryocytes, which bind and catabolize Mpl ligand. The clinical utility of recombinant Mpl ligands is currently under intense investigation. Early results have demonstrated a marked stimulation of megakaryocyte and platelet production with no apparent adverse effects. In patients with cancer who are treated with chemotherapy, the duration of thrombocytopenia was shorter in patients treated with Mpl ligand than in those receiving placebo. The eventual role of Mpl ligand in clinical practice will be determined by the results of many ongoing clinical studies.
Insights
Mpl ligand, also known as thrombopoietin, is crucial for platelet production. Recombinant Mpl ligand shows promise in stimulating platelet growth and reducing thrombocytopenia in cancer patients.
Area of Science:
- Hematology
- Stem Cell Biology
- Molecular Biology
Background:
- Mpl ligand (thrombopoietin) is a hematopoietic growth factor regulating platelet production.
- Deficiency in Mpl ligand leads to an over 80% decrease in megakaryocytes and platelets.
- Mpl ligand supports stem cells, multipotential cells, and erythroid precursors.
Purpose of the Study:
- To investigate the role of Mpl ligand in megakaryocytopoiesis and platelet production.
- To evaluate the clinical utility of recombinant Mpl ligands.
- To assess the impact of Mpl ligand on thrombocytopenia in cancer patients undergoing chemotherapy.
Main Methods:
- Animal studies involving Mpl ligand deficiency.
- Investigation of endogenous thrombopoietin production and regulation.
- Clinical trials assessing recombinant Mpl ligand efficacy and safety.
Main Results:
- Recombinant Mpl ligands demonstrate marked stimulation of megakaryocyte and platelet production.
- No apparent adverse effects were observed with recombinant Mpl ligand treatment.
- Patients treated with Mpl ligand experienced shorter durations of thrombocytopenia compared to placebo.
Conclusions:
- Mpl ligand plays a vital role in regulating platelet production and megakaryocytopoiesis.
- Recombinant Mpl ligands are a promising therapeutic agent for stimulating platelet production.
- Ongoing clinical studies will determine the full clinical utility of Mpl ligand in practice.